[12] Patent
[11] Patent No.:GC0007580  
[45] Date of Publishing the Grant of the Patent: 30/Apr /2018                48/2018  
Number of the Decision to Grant the Patent:2018/126031
Date of the Decision to Grant the Patent:15/Apr/2018

[21] Application No.:GCC/P/2003/2644

[22] Filing Date:7/5/2003

[30] Priority:

[33] State [32] Priority date [31] Priority No.
EP
10/5/2002
02010136.6

[72] Inventors:1- BERNHARD PICHLER،2- FRIEDER BAUSS،3- STEPHEN TURLEY

[73] Owner: F. HOFFMANN - LA ROCHE AG, grenzacherstrasse 124, CH-4070, Basel, Switzerland

[74] Agent: Kadasa Law Firm

  

 

  

[51]IPC:
Int. Cl.7: A61K3 1/662, 31/663, 47/04, 47/12, 47/26, 47/32, 47/34, 47/38, 9/00, 9/20, 9/28, 9/36; A61P 19/08, 19/10

[56] Cited Documents:

-ClinicalTrials.gov: MOBILE study - A Study on Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis, October 2002
-WO 0115703 A1 (SANTORA ARTHUR C IT; MERCK & CO INC (US); YATES A JHON (US); DAIFO) 08 March 2001
-Remington's Phamrmaceutical Sciences, 18th Edition, 1990: Chapter 100 - Patient compliance, pages 1813-1827
 
Examiner: PH. Mohammad S. AlMousa

[54] TREATMENT AND PREVENTION OF OSTEOPOROSIS
[57] Abstract: The present invention refers to the use of bisphosphonic acids or pharmaceutically acceptable salts thereof for the manufacture of medicaments for the prevention or the treatment of disorders characterized by pathologically increased bone resorption, especially for the prevention and treatment of osteoporosis.
No. of claims: 2


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.